Hide metadata

dc.date.accessioned2023-03-13T17:49:45Z
dc.date.available2023-03-13T17:49:45Z
dc.date.created2023-01-04T13:17:26Z
dc.date.issued2022
dc.identifier.citationSeborova, Karolina Hlavac, Viktor Holy, Petr Bjørklund, Sunniva Fleischer, Thomas Rob, Lukas Hruda, Martin Bouda, Jiri Mrhalova, Marcela Al Obeed Allah, Mohammad Moufaq Khatar Vodicka, Pavel Fiala, Ondrej Soucek, Pavel Kristensen, Vessela N. Vodickova, Ludmila Vaclavikova, Radka . Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy. Frontiers in Oncology. 2022, 12:1016958, 1-16
dc.identifier.urihttp://hdl.handle.net/10852/101408
dc.description.abstractEpithelial ovarian carcinoma (EOC) is known for high mortality due to diagnosis at advanced stages and frequent therapy resistance. Previous findings suggested that the DNA repair system is involved in the therapeutic response of cancer patients and DNA repair genes are promising targets for novel therapies. This study aimed to address complex inter-relations among gene expression levels, methylation profiles, and somatic mutations in DNA repair genes and EOC prognosis and therapy resistance status. We found significant associations of DUT expression with the presence of peritoneal metastases in EOC patients. The high-grade serous EOC subtype was enriched with TP53 mutations compared to other subtypes. Furthermore, somatic mutations in XPC and PRKDC were significantly associated with worse overall survival of EOC patients, and higher FAAP20 expression in platinum-resistant than platinum-sensitive patients was observed. We found higher methylation of RAD50 in platinum-resistant than in platinum-sensitive patients. Somatic mutations in BRCA1 and RAD9A were significantly associated with higher RBBP8 methylation in platinum-sensitive compared to platinum-resistant EOC patients. In conclusion, we discovered associations of several candidate genes from the DNA repair pathway with the prognosis and platinum resistance status of EOC patients, which deserve further validation as potential predictive biomarkers.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleComplex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy
dc.title.alternativeENEngelskEnglishComplex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy
dc.typeJournal article
dc.creator.authorSeborova, Karolina
dc.creator.authorHlavac, Viktor
dc.creator.authorHoly, Petr
dc.creator.authorBjørklund, Sunniva
dc.creator.authorFleischer, Thomas
dc.creator.authorRob, Lukas
dc.creator.authorHruda, Martin
dc.creator.authorBouda, Jiri
dc.creator.authorMrhalova, Marcela
dc.creator.authorAl Obeed Allah, Mohammad Moufaq Khatar
dc.creator.authorVodicka, Pavel
dc.creator.authorFiala, Ondrej
dc.creator.authorSoucek, Pavel
dc.creator.authorKristensen, Vessela N.
dc.creator.authorVodickova, Ludmila
dc.creator.authorVaclavikova, Radka
cristin.unitcode185,53,18,10
cristin.unitnameAvdeling for medisinsk genetikk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2100522
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Oncology&rft.volume=12:1016958&rft.spage=1&rft.date=2022
dc.identifier.jtitleFrontiers in Oncology
dc.identifier.volume12
dc.identifier.doihttps://doi.org/10.3389/fonc.2022.1016958
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2234-943X
dc.type.versionPublishedVersion
cristin.articleid116958
dc.relation.projectEC/H2020/856620


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International